A. Robert Bailey compensation by year
Bausch & Lomb Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $519,231 | $767,423 | $767,942 |
| Bonus | $200,000 | $0 | $0 |
| Stock awards | $2,049,705 | $3,558,049 | $1,714,561 |
| Option awards | $1,999,997 | $500,000 | $449,998 |
| Non-equity incentive | $430,816 | $687,582 | $673,200 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $14,850 | $15,525 | $27,250 |
| Total | $5,214,599 | $5,528,579 | $3,632,951 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Bausch & Lomb Corp DEF 14A filed April 10, 2026, accession 0001140361-26-014234, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Bausch & Lomb Corp filed document, accession 0001140361-26-014234. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 302,013 | $5,158,382 | — |
| RSU | 50,675 | $865,529 | — |
| RSU | 44,743 | $764,210 | — |
| RSU | 40,540 | $692,423 | — |
| RSU | 40,167 | $686,052 | — |
| RSU | 33,557 | $573,154 | — |
| RSU | 22,372 | $382,114 | — |
| RSU | 8,446 | $144,258 | — |
| Option | 67,751 | — | $16.85 |
| Option | 96,566 | — | $15.86 |
| Option | 143,062 | — | $17.50 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Bausch & Lomb Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2025 proxy (filed April 10, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-05 | Grant or award | — | 33,557 | $0.00 | 264,241 |
| 2026-04-24 | Tax withholding | — | 15,806 | $15.82 | 230,684 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Bausch & Lomb’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Brenton Saunders | Chairman of the Board and Chief Executive Officer | $32,194,326 |
| Sam Eldessouky | Executive Vice President and Chief Financial Officer | $4,962,441 |
| A. Robert Bailey · this page | Executive Vice President and Chief Legal Officer | $3,632,951 |
| Yehia Hashad | Executive Vice President of Research & Development and Chief Medical Officer | $2,789,501 |
| Andrew Stewart | President, Global Pharmaceuticals and International Consumer | $2,500,253 |
The full Bausch & Lomb compensation record
free company briefThis page is one person within Bausch & Lomb's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Bausch & Lomb proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Bausch & Lomb's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Bausch & Lomb's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order BLCO
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.